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Summary
Interactive effects between emodin and genistein were investigated using the rat vascular smooth muscle cell line A-10. Genistein significantly retarded the proliferation. While emodin alone also retarded the proliferation, its effect was reversed in the presence of genistein. It appeared that emodin cancelled the effect of genistein. Exposure to high concentrations of genistein resulted in a reduction of TNF-induced MCP-1 secretion. Concomitant treatments of emodin and genistein had more effect on TNF-induced MCP-1 secretion compared to emodin treatment alone. A slight decrease in TIMP-2 secretion was observed in 100 M genistein-treated cells, and the results of concomitant treatments of emodin and genistein showed the same tendencies as those seen with MCP-1 secretion. Consequently, it is likely that their effects on MCP-1 and TIMP-2 secretions were additive. With regard to MCP-1 and TIMP-2 secretions, it is suggested that emodin and genistein share the same signal transduction pathways, and thus reinforce the signal transduction to exert the additive effects. Conversely, emodin appeared to interfere with the effect of genistein on proliferation, suggesting that the mechanism of inhibition of proliferation is different from those of the other two phenomena. 
Materials and Methods

Chemicals and Cells
Treatments of Cells and Assays
The method used to measure 5-bromo-2-deoxyuridine (BrdU) incorporation during DNA synthesis was identical to that of Nagashima and Goto .
Approximately 7.5 10 4 cells in 0.5 ml of medium with or without 25 ng/ml (1.43 pM) human TNFwere cultured in each well of a 24-well culture plate for 24 hr followed by collection of medium.
Collected media were centrifuged at 1,000 g for 5 min to remove cell debris, and the resulting supernatants were subjected to assays. The levels of MCP-1 and TIMP-2 were quantified using , high concentration (100 M) of emodin inhibited proliferation considerably, and the treatment of genistein alone caused a marked dose-dependent retardation of A-10 cell proliferation (Fig. 1A) . The difference between the percent activities of 0 M and 100 M genistein-treated samples was 98.4 %. On the other hand, in the presence of genistein, emodin boosted the proliferation slightly (25 M) or markedly (50 M and 100 M) (Fig. 1A) . At 50 M and 100 M emodin, the differences between the percent activities of 0 M and 100 M genistein-treated samples decreased to 78.2 % and 1.5 %, respectively. As a result, it appeared that all the lines converged on 50 % activity of control at 100 M emodin (Fig. 1A) . Interpretation of these results is that emodin cancelled the effect of genistein. At 100 M emodin, its effect was predominant, and all the values were similar regardless of the presence of genistein. . Our results are consistent with previous reports that genistein inhibits MCP-1 secretion 3,6,8) .
As shown in Fig. 1B , concomitant treatments of emodin and genistein reduced TNF-induced MCP-1 secretion considerably more than emodin treatment alone, and the effect of genistein appeared to be dose-dependent. It is conceivable that their effects were additive and emodin did not interfere with the effect of genistein. These results (Fig. 1B) were totally different from those of BrdU incorporation (Fig. 1A) .
No one has reported the effect of genistein on TIMP-2 secretion. Thus, we investigated the effect of genistein on TIMP-2 secretion for the first time using A-10 cells (Table 2) . A slight but statistically significant (p < 0.05) decrease in TIMP-2 secretion was observed in 100 M genisteintreated samples (Table 2) . Kim et al. reported the effect of genistein on TIMP-2 mRNA levels 9, 10) , but not TIMP-2 secretion. According to their results, genistein down-regulated and up-regulated the expression of TIMP-2 in rat NK cells 9) and Jurkat T leukemia cells 10) , respectively.
With regard to TIMP-2 secretion (Fig. 1C) , although obvious dose-dependent effect of genistein was not observed, the results were basically the same as those of MCP-1 secretion (Fig. 1B) .
Consequently, it appeared that their effects on TIMP-2 secretion were additive. 
Discussion
In many cases, combination of the independent treatments results in the additive effects. Verma et al., for instance, reported that genistein and curcumin exhibited additive inhibitory effects on pesticide-induced proliferation using human breast cancer cell MCF-7 11) . Likewise, Tanos et al.
showed that tamoxifen enhanced the antiproliferative effect of genistein in human dysplastic epithelial breast cell lines 12) . We now report that the effects of concomitant treatments of emodin and genistein on MCP-1 and TIMP-2 secretions exhibited the same tendencies (Fig. 1B, 1C) . We suggest that in these four cases, genistein and its counterparts share signal transduction pathways, and therefore reinforce the signal transduction to exert the additive effects. On the contrary, emodin appeared to interfere with the effect of genistein on proliferation (Fig. 1A) , suggesting that the mechanism of inhibition of proliferation is different from those of the other two phenomena in A-10 cells. It is noteworthy that emodin is reported to exert the inhibition of kinase activities [13] [14] [15] [16] . It is possible that emodin inhibited certain kinases, and this inhibition antagonized the signal transduction of genistein. With respect to MCP-1 and TIMP-2 secretions, presumably different signal transduction pathway(s) to those involved in cell proliferation dominated, therefore, emodin boosted rather than interfered the effects of genistein.
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